Announced Thu, 21 May · 13:22 IST

Outcome of Board Meeting 21.05.2026

Revenue DeclinePat NegativeGoing ConcernDebt Equity ThresholdNegative Operating CashflowResults View source PDF

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.4%1-day move
₹56.38
prior close
₹55.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.0+1.2+4.4+9.6+15.1+20.9+16.4+15.3+17.0+14.6-1.7
Up moveDown movePending
AI summary

Krebs Biochemicals reported a net loss of Rs 1,693.31 Lacs for FY 2026, though an improvement from the Rs 2,692.40 Lacs loss in FY 2025. Revenue from operations declined sharply to Rs 2,373.16 Lacs from Rs 4,331.19 Lacs in the prior year—a 45% revenue decline. The company has negative net worth of Rs 16,275.47 Lacs and negative other equity of Rs 18,431.53 Lacs. Total borrowings stand at Rs 22,483.82 Lacs with a negative debt-equity ratio of (1.38). The Vizag manufacturing unit has remained closed since February 2025 following an Andhra Pradesh Pollution Control Board order. Operating cash flow was negative at Rs 192.05 Lacs. The statutory auditors issued an unmodified opinion.

Likely market impact

The company is in severe financial distress with negative net worth and declining revenues, raising substantial doubts about its ability to continue as a going concern despite the clean audit opinion.